Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® (rituximab)... Dec 18
rBIO, an early-stage synthetic biology company focused on reducing the cost of prescription drugs, has announced its first in-lab milestone: synthetic production of ... Dec 17
-Advertisements-